Immunome (IMNM)
(Delayed Data from NSDQ)
$12.28 USD
+0.19 (1.57%)
Updated Oct 18, 2024 03:59 PM ET
After-Market: $12.28 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$12.28 USD
+0.19 (1.57%)
Updated Oct 18, 2024 03:59 PM ET
After-Market: $12.28 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Zacks News
Immunome, Inc. (IMNM) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Immunome (IMNM) delivered earnings and revenue surprises of -28.95% and 9.77%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Cartesian Therapeutics, Inc. (RNAC) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Cartesian Therapeutics, Inc. (RNAC) delivered earnings and revenue surprises of 166.67% and 457.42%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Cytek Biosciences, Inc. (CTKB) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Cytek Biosciences (CTKB) delivered earnings and revenue surprises of -166.67% and 4.89%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Immunome, Inc. (IMNM) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Immunome (IMNM) delivered earnings and revenue surprises of 57.50% and 74.28%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Immunome, Inc. (IMNM) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Immunome (IMNM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for April 4th
by Zacks Equity Research
IMNM, SLOIF and TMQ have been added to the Zacks Rank #5 (Strong Sell) List on April 4, 2023.
Company News for Apr 2, 2024
by Zacks Equity Research
Companies In The News Are: SMTC, OXM, IMNM, GOOGL.
Immunome (IMNM) to Acquire Desmoid Tumor Candidate, Stock Up
by Zacks Equity Research
Immunome (IMNM) inks an asset purchase agreement with Ayala Pharmaceuticals to acquire the latter's investigational candidate, AL102, being developed for treating desmoid tumors. Stock rises.
Immunome (IMNM) Surges on Merger Agreement With Morphimmune
by Zacks Equity Research
Immunome's (IMNM) shares rise following its announcement to merge with Morphimmune. The synergy will help strengthen the development of oncology therapies.
Here's What Could Help Immunome, Inc. (IMNM) Maintain Its Recent Price Strength
by Zacks Equity Research
Immunome, Inc. (IMNM) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Immunome, Inc. (IMNM) is on the Move, Here's Why the Trend Could be Sustainable
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Immunome, Inc. (IMNM) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Recent Price Trend in Immunome, Inc. (IMNM) is Your Friend, Here's Why
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Immunome, Inc. (IMNM) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Immunome (IMNM) COVID-19 Cocktail Hold Lifted, Shares Gain
by Zacks Equity Research
Immunome (IMNM) gains as FDA lifts clinical hold on its Investigational New Drug (IND) application for its antibody cocktail (IMM-BCP-01) for the treatment of COVID-19.
Allogene (ALLO) CAR T Therapy for Myeloma Gets FDA RMAT Tag
by Zacks Equity Research
FDA grants RMAT designation to Allogene's (ALLO) CAR T cell product candidate for multiple myeloma, ALLO-715. The designation will help accelerate development and review of the candidate.
The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Incyte, Nektar Therapeutics, Immunome and Otonomy
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Incyte, Nektar Therapeutics, Immunome and Otonomy
Biotech Stock Roundup: Regulatory Updates From REGN, INCY, & Other Updates
by Zacks Equity Research
The biotech sector was in focus last week with regulatory and pipeline updates from quite a few companies like Regeneron (REGN), Incyte (INCY) and Nektar (NKTR).